BRPI0908050A2 - Furo-e tieno[3,2-c]piridinas - Google Patents

Furo-e tieno[3,2-c]piridinas

Info

Publication number
BRPI0908050A2
BRPI0908050A2 BRPI0908050-3A BRPI0908050A BRPI0908050A2 BR PI0908050 A2 BRPI0908050 A2 BR PI0908050A2 BR PI0908050 A BRPI0908050 A BR PI0908050A BR PI0908050 A2 BRPI0908050 A2 BR PI0908050A2
Authority
BR
Brazil
Prior art keywords
furo
thieno
pyridines
Prior art date
Application number
BRPI0908050-3A
Other languages
English (en)
Inventor
Mark J Mulvihill
Jing Wang
Xin Chen
Ti Wang
An-Hu Li
Arno G Steinig
Andrew Kleinberg
Qinghua Weng
Hanqing Dong
Meizhong Jin
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of BRPI0908050A2 publication Critical patent/BRPI0908050A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0908050-3A 2008-02-06 2009-02-06 Furo-e tieno[3,2-c]piridinas BRPI0908050A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6380008P 2008-02-06 2008-02-06
US11955308P 2008-12-03 2008-12-03
PCT/US2009/033311 WO2009100282A1 (en) 2008-02-06 2009-02-06 Furo-and thieno[3,2-c] pyridines

Publications (1)

Publication Number Publication Date
BRPI0908050A2 true BRPI0908050A2 (pt) 2015-08-11

Family

ID=40524808

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908050-3A BRPI0908050A2 (pt) 2008-02-06 2009-02-06 Furo-e tieno[3,2-c]piridinas

Country Status (19)

Country Link
US (1) US8022206B2 (pt)
EP (1) EP2265616B8 (pt)
JP (1) JP2011511094A (pt)
KR (1) KR20110014971A (pt)
CN (1) CN102007127A (pt)
AR (1) AR070317A1 (pt)
AU (1) AU2009212338A1 (pt)
BR (1) BRPI0908050A2 (pt)
CA (1) CA2711078A1 (pt)
CL (1) CL2009000275A1 (pt)
EA (1) EA201070929A1 (pt)
ES (1) ES2451024T3 (pt)
IL (1) IL206758A0 (pt)
MX (1) MX2010008638A (pt)
PE (1) PE20091414A1 (pt)
TW (1) TW200944201A (pt)
UY (1) UY31638A1 (pt)
WO (1) WO2009100282A1 (pt)
ZA (1) ZA201005554B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2534156A1 (en) * 2010-02-11 2012-12-19 OSI Pharmaceuticals, LLC 7-aminofuropyridine derivatives
WO2011109593A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Substituted-5-aminopyrrolo/pyrazolopyridines
US8916593B2 (en) * 2010-05-04 2014-12-23 Pfizer Inc. Alkoxy-substituted 2-aminopyridines as ALK inhibitors
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
TWI504350B (zh) * 2010-09-01 2015-10-21 Du Pont 殺真菌吡唑及其混合物
US10614666B2 (en) 2011-04-20 2020-04-07 Video Gaming Technologies, Inc. Gaming machines with free play bonus mode presenting only winning outcomes
JP6118808B2 (ja) * 2011-10-31 2017-04-19 ザ メソジスト ホスピタル リサーチ インスティテュート ヒトグリオームを治療するためのｍａｏ標的化／探索部分を含む化合物
EP2828267B1 (en) * 2012-03-23 2019-10-30 Memorial Sloan-Kettering Cancer Center TREATMENT OF PANCREATIC AND RELATED CANCERS WITH 5-ACYL-6,7-DIHYDROTHIENO[3,2-c]PYRIDINES
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
KR101582852B1 (ko) 2012-05-24 2016-01-07 서울대학교 산학협력단 타우 단백질 매개 신경 퇴행성 질환 치료제
WO2014210255A1 (en) 2013-06-26 2014-12-31 Abbvie Inc. Primary carboxamides as btk inhibitors
WO2015138925A1 (en) * 2014-03-14 2015-09-17 University Of Utah Research Foundation Ron inhibitors for use in preventing and treating bone loss
CN103923081B (zh) * 2014-04-14 2017-06-27 武汉光谷人福生物医药有限公司 化合物及其制备方法和应用
JP6864953B2 (ja) 2014-12-09 2021-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ａｘｌに対するヒトモノクローナル抗体
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
CN106866447A (zh) * 2017-03-30 2017-06-20 成都绿林科技有限公司 一种合成对乙酰基苯甲酰胺的方法
US10957159B2 (en) 2018-04-12 2021-03-23 Aristocrat Technologies Australia Pty Limited Gaming machine and method for displaying a free spin count-up
US11427596B2 (en) * 2019-07-19 2022-08-30 Indian Institute of Technology Indore Metal-free solvent-free synthesis of fused-pyrido heterocycles and biomedical applications
UY39890A (es) * 2021-08-10 2023-03-31 Jacobio Pharmaceuticals Co Ltd Compuestos con diana en mutante de p53
CN119998290A (zh) 2022-10-03 2025-05-13 公立大学法人横滨市立大学 具有二环性结构的咪唑并吡啶衍生物
JP2026500029A (ja) * 2022-12-15 2026-01-05 睿健毅聯医薬科技（成都）有限公司 間葉系細胞から上皮細胞への形質転換及びリプログラミングを誘導する誘導剤

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2003002929A0 (en) 2001-06-23 2003-12-31 Aventis Pharma Inc Pyrrolopyrimidines as protein kinase inhibitors
US20040235867A1 (en) * 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
JP4505228B2 (ja) * 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｒｈｏ−キナーゼ阻害剤
US7704995B2 (en) 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
WO2004069160A2 (en) 2003-01-28 2004-08-19 Smithkline Beecham Corporation Chemical compounds
DK1603570T5 (da) 2003-02-26 2013-12-09 Sugen Inc Aminoheteroarylforbindelser som proteinkinaseinhibitorer
WO2004100947A2 (en) * 2003-05-06 2004-11-25 Smithkline Beecham Corporation Novel chemical compounds
US20050026944A1 (en) * 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
US7674907B2 (en) * 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
ES2355923T3 (es) 2004-08-26 2011-04-01 Pfizer, Inc. Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa.
EP1786777A1 (en) 2004-08-26 2007-05-23 Pfizer, Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
DE602005020465D1 (de) 2004-08-26 2010-05-20 Pfizer Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
EP1869052A1 (en) * 2005-04-06 2007-12-26 AstraZeneca AB Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
BRPI0520482A2 (pt) * 2005-08-16 2009-05-12 Hoffmann La Roche amidas do ácido 4-amino-tieno [3,2-c] piridina-7-carboxìlico
WO2007027855A2 (en) * 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
US20080255184A1 (en) * 2005-11-04 2008-10-16 Smithkline Beecham Corporation Thienopyridine B-Raf Kinase Inhibitors
DK1963302T3 (da) 2005-12-05 2013-04-02 Pfizer Prod Inc Polymorfer af en C-MET/HGFR-inhibitor
US7989461B2 (en) * 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
JP2009533327A (ja) 2006-03-22 2009-09-17 バーテックス ファーマシューティカルズ インコーポレイテッド 増殖性疾患を処置するためのｃ−ＭＥＴキナーゼ阻害剤
WO2007124181A2 (en) 2006-04-21 2007-11-01 Amgen Inc. Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
JP2010514695A (ja) 2006-12-21 2010-05-06 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物および方法およびそのための適応症
CL2008001540A1 (es) 2007-05-29 2009-05-22 Sgx Pharmaceuticals Inc Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
JP2011500778A (ja) 2007-10-25 2011-01-06 アストラゼネカ・アクチエボラーグ ピリジン及びピラジン誘導体−０８３
CL2008003449A1 (es) 2007-11-21 2010-02-19 Imclone Llc Anticuerpo o fragmentos del mismo contra el receptor de proteína estimulante de macrófagos/ron; composición farmacéutica que lo comprende; uso para inhibir angiogénesis, crecimiento tumoral, proliferación, migración e invasión de células tumorales, activación de ron o fosforilación de mapk y/o akt; y uso para tratar cáncer.
AU2009246263B2 (en) 2008-05-14 2014-08-21 Amgen Inc. Combinations VEGF(R) inhibitors and hepatocyte growth factor (c-Met) inhibitors for the treatment of cancer
KR101034351B1 (ko) 2008-05-14 2011-05-16 한국화학연구원 신규 벤즈옥사졸로 치환된 피리딘 유도체 또는 이의약학적으로 허용가능한 염, 이의 제조방법 및 이를유효성분으로 함유하는 이상세포 성장 질환의 예방 및치료용 약학적 조성물

Also Published As

Publication number Publication date
AU2009212338A1 (en) 2009-08-13
US8022206B2 (en) 2011-09-20
EA201070929A1 (ru) 2011-04-29
ES2451024T3 (es) 2014-03-26
UY31638A1 (es) 2009-09-30
AR070317A1 (es) 2010-03-31
KR20110014971A (ko) 2011-02-14
EP2265616A1 (en) 2010-12-29
EP2265616B1 (en) 2013-11-20
CL2009000275A1 (es) 2009-06-12
ZA201005554B (en) 2011-04-28
PE20091414A1 (es) 2009-09-23
JP2011511094A (ja) 2011-04-07
US20090197864A1 (en) 2009-08-06
CA2711078A1 (en) 2009-08-13
WO2009100282A1 (en) 2009-08-13
IL206758A0 (en) 2010-12-30
CN102007127A (zh) 2011-04-06
EP2265616B8 (en) 2014-01-08
TW200944201A (en) 2009-11-01
MX2010008638A (es) 2010-08-30

Similar Documents

Publication Publication Date Title
BRPI0908050A2 (pt) Furo-e tieno[3,2-c]piridinas
ATE555107T1 (de) 2-aza-bicyclo-ä2,2,1-üheptan-derivate
DOP2007000080A (es) Piridin [3,4-b] pirazinonas
BRPI0914657A2 (pt) piridin-2-onae piridazin-3-onas substituídas
BRPI0907563A2 (pt) Derivados de 4,5-di-hidro-xazol-2-il amina
NO2021006I1 (no) Quofenix, delafloksacin
BRPI1006113A2 (pt) "derivado de piridina".
BRPI0811718A2 (pt) Derivados de 3,3-espiroindolinona
EP2272042A4 (en) SMART CAR COMPLETION
BRPI0914533A2 (pt) "métodos"
BRPI0915064A2 (pt) derivados de qunoxalinadiona
DE602008005634D1 (de) 1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivate
UY33125A (es) Diaza-espiro-[5,5]-undecanos
EP2344471A4 (en) 7-PIPERIDINALKYL-3,4-dihydroquinolone DERIVATIVE
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI0906357A2 (pt) Derivados de oxazepinopirimidona arilamida substituídos
EP2257169A4 (en) TETRAHYDROTHIENPYRIDINE
BRPI0911625A2 (pt) Métodos
DE102008005493A8 (de) 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
ATE545635T1 (de) Substituierte n-oxidpyrazinderivate
BRPI0815059A2 (pt) Derivado de 1,3-di-hidroisoindol
BRPI0922652A2 (pt) Derivados de quinazolinamida
BRPI0913234A2 (pt) derivados de tiazolilpiperidina
BRPI1008173A2 (pt) "derivados de piridina espiroindolinona"
EP2459573A4 (en) SUBSTITUTED 1,2-AZABORIN HETEROCYCLES

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2367 DE 17-05-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.